Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Takeda Escapes COVID Impact With 2% Underlying Growth
R&D Spend To Rise 15%
May 12 2021
•
By
Ian Haydock
Takeda spends to progress Wave 1 pipeline • Source: Takeda
More from Business
More from Scrip